- Dr. Brooks is a veteran drug development leader whose experience includes roles at Pfizer, 4D Molecular Therapeutics, and Gilead Life Sciences, which directly supports Solid's focus on both neuromuscular and cardiac diseases -
CHARLESTOWN, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company developing precision genetic medicines for both neuromuscular and cardiac diseases, today announced the appointment of Gabriel Brooks, M.D., as Chief Medical Officer.
"We are excited to welcome Dr. Brooks to Solid Biosciences during this pivotal time in our company's history, advancing towards the clinic with our next generation gene therapy for Duchenne and furthering our diversified pipeline of both neuromuscular and cardiac gene therapies," said Bo Cumbo, President and Chief Executive Officer of Solid Biosciences. "Dr. Brooks' impressive accomplishments, specifically in cardiovascular genetic medicine, will bring valuable expertise and insights to our leadership team. His broad experience in precision genetic medicine will be vital to Solid as we work to bring hope to those patients living with these devastating genetic diseases."
Prior to joining Solid Biosciences, Dr. Brooks was Rare Cardiovascular Therapeutic Area Head in the Rare Disease Research Unit at Pfizer. While there, he directed the translational development of a range of precision AAV gene therapies for dilated, arrhythmogenic, and hypertrophic cardiomyopathies. Additionally, Dr. Brooks previously served as the vice president of research and development at 4D Molecular Therapeutics, where he oversaw translational development of AAV gene therapies for Anderson Fabry and oversaw first-in-human dosing of AAV gene therapies for two ophthalmologic indications (choroideremia and X-linked retinitis pigmentosa). Previously, Dr. Brooks led a successful Phase III registrational study of flurpiridaz at GE Life Sciences, and led several cardiovascular clinical trials in rare and large market indications while at Gilead Life Sciences.
"I am honored ...